Multicenter Safety, Feasibility and Pharmacokinetic Phase I Trial of ModraDoc006/r in Patients With Metastatic Castration-resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Docetaxel (Primary) ; Ritonavir (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Modra Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.
- 26 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2019.